Abstract

The objectives of this pilot project are to apply recent advances in the technologies of microfluidics, polymer surface chemistry and laser-scanning fluorometry to the task of simultaneously measuring the status of multiple protein1enzyme molecular targets in small clinical samples. The application of advanced technologies to the production of antibody arrays, and the technologies and protocols for executing the assays will allow straight-forward application of standard biochemical and immunological techniques. The goals of the project are 1) to miniaturize classical techniques of protein immunochemistry, through the modification and adaptation of established immunological methods of sandwich antibody assay and the use of liquid handling and laser-fluorometric technologies adapted from DNA microarray technology, and 2) to develop methods to allow these assays to be multiplexed so that several different endpoints can be analyzed in a single patient sample.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA090821-02
Application #
6563984
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-01-01
Project End
2002-12-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
2
Fiscal Year
2002
Total Cost
$296,752
Indirect Cost

  Institution

Name
University of Arizona
Department
Type
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85721

  Publications

Stephen, Renu M; Pagel, Mark D; Brown, Kathy et al. (2012) Monitoring the development of xenograft triple-negative breast cancer models using diffusion-weighted magnetic resonance imaging. Exp Biol Med (Maywood) 237:1273-80
Ihle, N T; Powis, G; Kopetz, S (2011) PI-3-Kinase inhibitors in colorectal cancer. Curr Cancer Drug Targets 11:190-8
Ihle, Nathan T; Lemos Jr, Robert; Wipf, Peter et al. (2009) Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 69:143-50
Baker, Amanda F; Koh, Mei Y; Williams, Ryan R et al. (2008) Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer. Pancreas 36:178-86
Koh, Mei Y; Spivak-Kroizman, Taly; Venturini, Sara et al. (2008) Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol Cancer Ther 7:90-100
Bagatell, Rochelle; Gore, Lia; Egorin, Merrill J et al. (2007) Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res 13:1783-8
Powis, Garth; Wipf, Peter; Lynch, Stephen M et al. (2006) Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase. Mol Cancer Ther 5:630-6
Baker, Amanda F; Dragovich, Tomislav; Tate, Wendy R et al. (2006) The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma. J Lab Clin Med 147:83-90
Raghunand, Natarajan; Jagadish, Bhumasamudram; Trouard, Theodore P et al. (2006) Redox-sensitive contrast agents for MRI based on reversible binding of thiols to serum albumin. Magn Reson Med 55:1272-80
Williams, Ryan; Baker, Amanda F; Ihle, Nathan T et al. (2006) The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling. Cancer Chemother Pharmacol 58:444-50

Showing the most recent 10 out of 26 publications